PBMCs from 9 patients with CLL were treated with BTLA blocking antibodies for 72 h and, then, NK and T cell anti-leukemic responses against CLL-derived MEC-1 cells were evaluated (Fig. 4B). Here, BTLA is linked to B-cell chronic lymphocytic leukemia.